Pacifica Partners’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.74K | Hold |
2,926
| – | – | ﹤0.01% | 450 |
|
|
2025
Q1 | $1.22K | Hold |
2,926
| – | – | ﹤0.01% | 476 |
|
|
2024
Q4 | $1.51K | Hold |
2,926
| – | – | ﹤0.01% | 444 |
|
|
2024
Q3 | $2.65K | Hold |
2,926
| – | – | ﹤0.01% | 442 |
|
|
2024
Q2 | $2.67K | Hold |
2,926
| – | – | ﹤0.01% | 451 |
|
|
2024
Q1 | $3.71K | Hold |
2,926
| – | – | ﹤0.01% | 430 |
|
|
2023
Q4 | $2.93K | Hold |
2,926
| – | – | ﹤0.01% | 470 |
|
|
2023
Q3 | $3.83K | Hold |
2,926
| – | – | ﹤0.01% | 433 |
|
|
2023
Q2 | $3.95K | Hold |
2,926
| – | – | ﹤0.01% | 390 |
|
|
2023
Q1 | $4.05K | Hold |
2,926
| – | – | ﹤0.01% | 404 |
|
|
2022
Q4 | $3.08K | Hold |
2,926
| – | – | ﹤0.01% | 397 |
|
|
2022
Q3 | $4K | Hold |
2,926
| – | – | ﹤0.01% | 384 |
|
|
2022
Q2 | $4K | Hold |
2,926
| – | – | ﹤0.01% | 390 |
|
|
2022
Q1 | $4K | Hold |
2,926
| – | – | ﹤0.01% | 386 |
|
|
2021
Q4 | $6K | Hold |
2,926
| – | – | ﹤0.01% | 352 |
|
|
2021
Q3 | $8K | Hold |
2,926
| – | – | 0.01% | 317 |
|
|
2021
Q2 | $8K | Hold |
2,926
| – | – | 0.01% | 308 |
|
|
2021
Q1 | $7K | Hold |
2,926
| – | – | 0.01% | 298 |
|
|
2020
Q4 | $5K | Hold |
2,926
| – | – | ﹤0.01% | 297 |
|
|
2020
Q3 | $3K | Hold |
2,926
| – | – | ﹤0.01% | 297 |
|
|
2020
Q2 | $2K | Hold |
2,926
| – | – | ﹤0.01% | 339 |
|
|
2020
Q1 | $2K | Hold |
2,926
| – | – | ﹤0.01% | 328 |
|
|
2019
Q4 | $3K | Buy |
+2,926
| New | +$3K | ﹤0.01% | 313 |
|